NCT01985061View on ClinicalTrials.gov

Evaluation of 3 Different Doses of IV Busulfan

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

177

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 7, 2026

Study Completion Date

July 7, 2026

Conditions

Myelodysplastic SyndromeAcute Myeloid Leukemia

Interventions

DRUG

BX2

DRUG

BX3

DRUG

BX4-Suspended

Suspended

Trial Locations (1)

13009

Institut Paoli Calmettes, Marseille

All Listed Sponsors

lead

Institut Paoli-Calmettes

OTHER